Other names
This indicator shows the number and percent of people with diabetes receiving dulaglutide regularly. Regular use was defined as dulaglutide dispensed in three or more quarters in a year.
Glucagon-like peptide-1 (GLP-1) receptor agonists such as dulaglutide are available since September 2021 and fully funded for the treatment of people with poorly controlled type 2 diabetes despite treatment who are at high risk of cardiovascular disease or have renal complications.
Understanding variation in dispensing these newer medicines is important for optimising diabetes care and ensuring that patients receive the most appropriate treatments.
People with diabetes dispensed dulaglutide in three or four quarters in the relevant year
Numerator detail
Formulation ID 414925 dulaglutide
Count of distinct master NHIs identified as having diabetes as per the VDR
Denominator exclusions
Brief description of any criteria resulting in removal of patients/events from the denominator (eg patients who should not receive the process or are not eligible for the outcome of interest).
An example of a denominator exclusion is to “exclude women who have had bilateral mastectomy from the denominator for a measure of screening mammography.
Disaggregation
For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile.
For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).